Everest Medicines Secures Taiwan Approval for XERAVA® in Treating Complicated Intra-Abdominal Infections in Adults

"The NDA approval of XERAVA® in Taiwan marks an important step towards bringing this novel, critical therapy for complicated intra-abdominal infections...

September 28, 2023 | Thursday | News
HUTCHMED Completes Patient Enrollment for Tazemetostat Study in Chinese Follicular Lymphoma

The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of ...

September 12, 2023 | Tuesday | News
Bristol Myers Squibb Signs $50M Deal to Address Immune-Mediated Diseases in Asia

US-based startup Zenas BioPharma has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialise ob...

September 07, 2023 | Thursday | News
Hong Kong Department of Health has Approved the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System

Uro-G offers a viewing angle of 120°, both 210° upward and 130° downward motion angles, and a 90° angle of rotation clockwise and countercl...

August 15, 2023 | Tuesday | News
HUTCHMED's Fruquintinib Combo Receives Breakthrough Designation in China for Advanced Endometrial Cancer, Enrollment Complete

It is a multi-center, open-label clinical study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab. Entry criteria include ...

July 20, 2023 | Thursday | News
HUTCHMED Begins Phase I Study of Novel SHP2 Inhibitor for Advanced Solid Tumors in China

The clinical trial is a multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy profile of HMPL-415 ...

July 10, 2023 | Monday | News
HKSTP and eWTP Arabia Capital Welcome Saudi Delegation to Boost I&T Collaboration

Chief Executive John Lee met with H.E. Eng. Abdullah Al-Swaha, Minister of Communications and Information Technology of Kingdom of Saudi Arabia again fol...

July 04, 2023 | Tuesday | News
Sirnaomics Initiates Phase I Study of RNAi Therapeutic STP122G for Anticoagulant Treatment

STP122G is part of the Group's GalAhead™ Factor XI RNAi therapeutic program, which has applications across a broad range of disease indications such ...

June 02, 2023 | Friday | News
Takeda and HUTCHMED's Fruquintinib NDA for Metastatic Colorectal Cancer Gets Priority Review

— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO...

May 26, 2023 | Friday | News
SINOVAC's CoronaVac® meets Hong Kong's need for COVID-19 vaccines

On March 31, 2023, the government of the Hong Kong Special Administrative Region announced that, from April 20, high-risk groups will be able to receive fr...

May 11, 2023 | Thursday | News
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...

April 18, 2023 | Tuesday | Regulatory
Asia Pacific Cancer Biomarkers Market Analysis

Cancer is one of the leading causes of death across Asian countries. According to a report published by Janssen Asia Pacific, in 2017, overall, there wer...

April 07, 2023 | Friday | News
Manulife Survey Reveals: People in Asia Strive for Longer and Healthier Retirement by Expanding their Health Span

Survey of 7,000+ people in Asia shows expectation of early retirement, early deterioration in health Concerns about cost of well-being nu...

March 29, 2023 | Wednesday | News
Sihuan Pharmaceutical(0460.HK): Huisheng Biopharmaceutical Successfully Completed the A + Round of Financing

Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "...

January 05, 2023 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2023 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in